Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The newly approved single-tablet regimen contains the integrase inhibitor bictegravir plus emtricitabine and tenofovir alafenamide.
Scientists tested the effects of the broadly neutralizing antibody PGT121 and the immune-stimulating agent GS-9620 in monkeys.
This long-acting drug is linked to undetectable viral loads in former prisoners with substance use disorders.
The Food and Drug Administration approves antibody treatment Trogarzo for multidrug-resistant HIV.
A star-shaped drug capsule could permit weekly dosing of HIV meds.
The risk for cervical cancer is lower for women living with HIV on treatment.
The researchers studied a new compound that blocked a key viral protein that prompts infected cells to produce more virus.
Juluca is a single-tablet regimen for HIV.
A recent small study compared objective and subjective fatigue among those with and without HIV who were age 50 and older.
Quitting, even at age 40, can drastically lower this risk.
However, compared with the general population, HIV-positive individuals remain at higher risk for a slew of malignancies.
Getting 70 percent of the HIV population virally suppressed by 2020 would prevent a vast number of deaths over two decades.
Cure studies typically require a temporary break in HIV treatment, often with little promise of a personal benefit to the participant.
Three antibodies combined into one protected monkeys against a simian version of HIV, opening the door for human trials.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.